Chinese NASH-Focused Biotech Firm Sciwind Biosciences Raises $29M Series A Round

Login to View

Sciwind Biosciences, a Chinese drug research and development company for metabolic diseases, announced on Wednesday that it has raised a nearly RMB200 million (US$29.58 million) series A round of financing led by Beijing-based investment firm Legend Capital.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in